CVS Health Corporation: This Form 144 notifies a proposed sale of 7,500 shares of CVS common stock through Merrill Lynch on the NYSE with an aggregate market value of $532,275, scheduled approximately for 08/20/2025. The filer reports that these shares were received as director compensation across multiple grant dates between 2012 and 2022, totaling specific lots of 1,428; 2,222; 1,546; 2,099; and 205 shares. No securities were reported sold in the past three months. The notice includes the standard representation that the selling person does not possess undisclosed material adverse information.
CVS Health Corporation filed an 8-K reporting documentation related to a debt offering process. The filing references an Underwriting Agreement dated August 11, 2025 naming Barclays Capital Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC as representatives of the underwriters. The forms of four notes with maturities labeled 2032, 2035, 2055 and 2065 are included as exhibits, along with the opinion and consent of Wachtell, Lipton, Rosen & Katz. The cover page Inline XBRL data is noted as filed. The filing is signed by Brian Newman, Executive Vice President and Chief Financial Officer on August 15, 2025.